311 related articles for article (PubMed ID: 31973681)
1. Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves' Disease: A Nationwide Population-Based Study.
Brito JP; Payne S; Singh Ospina N; Rodriguez-Gutierrez R; Maraka S; Sangaralingham LR; Iñiguez-Ariza NM; Montori VM; Stan MN
Thyroid; 2020 Mar; 30(3):357-364. PubMed ID: 31973681
[No Abstract] [Full Text] [Related]
2. Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey.
Törring O; Watt T; Sjölin G; Byström K; Abraham-Nordling M; Calissendorff J; Cramon PK; Filipsson Nyström H; Hallengren B; Holmberg M; Khamisi S; Lantz M; Wallin G
Thyroid; 2019 Mar; 29(3):322-331. PubMed ID: 30667296
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Graves' Disease Patients Following Antithyroid Drugs, Radioactive Iodine, or Thyroidectomy as the First-line Treatment.
Liu X; Wong CKH; Chan WWL; Tang EHM; Woo YC; Lam CLK; Lang BHH
Ann Surg; 2021 Jun; 273(6):1197-1206. PubMed ID: 33914484
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis.
Sundaresh V; Brito JP; Wang Z; Prokop LJ; Stan MN; Murad MH; Bahn RS
J Clin Endocrinol Metab; 2013 Sep; 98(9):3671-7. PubMed ID: 23824415
[TBL] [Abstract][Full Text] [Related]
5. The Long-Term Outcome of Treatment for Graves' Hyperthyroidism.
Sjölin G; Holmberg M; Törring O; Byström K; Khamisi S; de Laval D; Abraham-Nordling M; Calissendorff J; Lantz M; Hallengren B; Filipsson Nyström H; Wallin G
Thyroid; 2019 Nov; 29(11):1545-1557. PubMed ID: 31482765
[No Abstract] [Full Text] [Related]
6. Comparative Effectiveness of Treatment Choices for Graves' Hyperthyroidism: A Historical Cohort Study.
Sundaresh V; Brito JP; Thapa P; Bahn RS; Stan MN
Thyroid; 2017 Apr; 27(4):497-505. PubMed ID: 28049375
[TBL] [Abstract][Full Text] [Related]
7. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T
Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440
[TBL] [Abstract][Full Text] [Related]
8. Definitive treatment of Graves' disease in children and adolescents.
Król A; Czarniecka A; Jarząb B
Endokrynol Pol; 2021; 72(6):661-665. PubMed ID: 34855196
[TBL] [Abstract][Full Text] [Related]
9. Does thyroidectomy, radioactive iodine therapy, or antithyroid drug treatment alter reactivity of patients' T cells to epitopes of thyrotropin receptor in autoimmune thyroid diseases?
Soliman M; Kaplan E; Abdel-Latif A; Scherberg N; DeGroot LJ
J Clin Endocrinol Metab; 1995 Aug; 80(8):2312-21. PubMed ID: 7543112
[TBL] [Abstract][Full Text] [Related]
10. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review.
Acharya SH; Avenell A; Philip S; Burr J; Bevan JS; Abraham P
Clin Endocrinol (Oxf); 2008 Dec; 69(6):943-50. PubMed ID: 18429949
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes of Repeated Radioactive Iodine Therapy for Graves' Disease.
Kim MJ; Cho SW; Kim YA; Choi HS; Park YJ; Park DJ; Cho BY
Endocrinol Metab (Seoul); 2022 Jun; 37(3):524-532. PubMed ID: 35709827
[TBL] [Abstract][Full Text] [Related]
12. Changes in Thyrotropin Receptor Antibody Levels Following Total Thyroidectomy or Radioiodine Therapy in Patients with Refractory Graves' Disease.
Kim J; Choi MS; Park J; Park H; Jang HW; Choe JH; Kim JH; Kim JS; Cho YS; Choi JY; Kim TH; Chung JH; Kim SW
Thyroid; 2021 Aug; 31(8):1264-1271. PubMed ID: 33947272
[No Abstract] [Full Text] [Related]
13. Treatment Modality and Risk of Heart Failure in Patients With Long-Standing Graves' Disease: A Nationwide Population-Based Cohort Study.
Song E; Kim M; Park S; Park MJ; Kim JA; Roh E; Yu JH; Kim NH; Seo JA; Kim SG; Kim NH; Choi KM; Baik SH; Yoo HJ
Front Endocrinol (Lausanne); 2021; 12():761782. PubMed ID: 34690936
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of single-session radiofrequency ablation (RFA) in rendering euthyroidism for persistent/relapsed Graves' disease, a pilot study.
Fung MHM; Lang BHH
Eur Radiol; 2023 Sep; 33(9):6534-6544. PubMed ID: 37036479
[TBL] [Abstract][Full Text] [Related]
15. "Block-and-replace" treatment in Graves' disease: experience in a cohort of pediatric patients.
Vigone MC; Peroni E; Di Frenna M; Mora S; Barera G; Weber G
J Endocrinol Invest; 2020 May; 43(5):595-600. PubMed ID: 31713721
[TBL] [Abstract][Full Text] [Related]
16. The adjunctive use of carbimazole during radioactive iodine treatment reduces the cure rate of Graves' disease.
Docrat F; Mokoena T; Karusseit VOL; Ankrah AO
S Afr Med J; 2021 Feb; 111(2):176-179. PubMed ID: 33944730
[TBL] [Abstract][Full Text] [Related]
17. Use of cold iodine in patients with Graves' disease: observations from a clinical practice.
Hao ST; Reasner CA; Becker RA
Endocr Pract; 2001; 7(6):438-42. PubMed ID: 11747279
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility analysis comparing radioactive iodine, anti-thyroid drugs and total thyroidectomy for primary treatment of Graves' disease.
Donovan PJ; McLeod DS; Little R; Gordon L
Eur J Endocrinol; 2016 Dec; 175(6):595-603. PubMed ID: 27634939
[TBL] [Abstract][Full Text] [Related]
19. Long-term monitoring of Graves’ disease in children and adolescents: a single-center experience.
Tunç S; Köprülü Ö; Ortaç H; Nalbantoğlu Ö; Dizdarer C; Demir K; Özkan B
Turk J Med Sci; 2019 Apr; 49(2):464-471. PubMed ID: 30862149
[TBL] [Abstract][Full Text] [Related]
20. Increased Risk of Radioiodine Treatment Failure Associated with Graves Disease Refractory to Methimazole.
Kwak JJ; Altoos R; Jensen A; Altoos B; McDermott MT
Endocr Pract; 2020 Nov; 26(11):1312-1319. PubMed ID: 33471662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
